To determine risk factors for progression of diabetic retinopathy, a study was conducted in 92 patients with diabetes whose HbA1c levels were more than 9.5% when they were admitted to our hospital.
The progression of retinopathy was observed in 50% of the patients during 12 months after admission. Their cases were diagnosed as preproliferative retinopathy. The duration of no-treatment, serum cholesterol level, blood pressure and proteinuria were significantly greater in the deterioration group of retinopathy than in the no-deterioration group. Nerve conduction velocity was significantly lower in the deterioration group of retinopathy than in the no-deterioration group. The reduction of HbA1c level during the period of 3 months after admission was significantly higher in the deterioration group than in the improved group. In the patients whose initial levels of HbA1c were less than 10%, the deterioration of retinopathy was not observed. In conclusion, these findings suggest that the duration of no-treatment, serum cholesterol level, blood pressure, proteinuria, nerve conduction velocity, retinopathy severity, the HbA1c level at admission and the reduction of HbA1c level during the 3-month period are risk factors for the progression of retinopathy.

A 62-year-old woman was adimitted to our hospital because of thirst and a body weight loss of 9kg. She had a history of vasospastic breast pang 5months before. The level of fasting plasma glucose was 320 mg/dl and the level of HbA_1c was 13.0%. The autoantibody to glutamic acid decarboxylase was positive. The level of urine C-peptide was 28.6μg/day. She rejected insulin injections and was treated with glibenclamide. The level of urine C-peptide increased to 70.0μg/day. The disease was controlled with the levels of 6.0% of HbA_1c. But her condition became uncontrollable gradually after 6 months and she was treated by insulin therapy.
Insulin secretion in type 1 diabetes mellitus was transiently improved by sulfony 1 urea. This suggests that not only the insulin secretion but also glucotoxicity plays an important role in early stage of type 1 diabetes mellitus.

The self-monitoring of blood glucose is a recommendable method for control of diabetes mellitus. But few reports of the prospective insulin sliding scale for outpatients were available in Japan. To elucidate the efficacy of the prospective insulin sliding scale for outpatients with diabetes mellitus, 14 insulin-treated patients who usedwith the prospective insulin sliding scale (scale group) and 14 insulin-treated patients who did not use with the prospective insulin sliding scale (control group) were studied over a period of 6 months.
The control group showed no significant change of Hb Aic level. But the scale group showed a significant reduction in Hb Aic level at 5 months (8.37 ± 1.14% to 7.50 ±1.42%, p<0.008). The scale group had an almost two fold increase in the frequency in hypoglycemia. However, there was no severe hypoglycamia. There were weight gains in the control group and scale group, but there was no difference between control group and scale group.
These data suggest that the prospective insulin sliding scale is useful for the better control of diabetes mellitus.

AIMTo evaluate the safety and efficacy of an extract of Ganoderma lucidum that shows the strongest 5alpha-reductase inhibitory activity among the extracts of 19 edible and medicinal mushrooms by a double-blind, placebo-controlled, randomized and dose-ranging study in men with lower urinary tract symptoms (LUTS).

METHODSIn this trial, we randomly assigned 88 men over the age of 49 years who had slight-to-moderate LUTS to 12 weeks of treatment with G. lucidum extract (6 mg once a day) or placebo. The primary outcome measures were changes in the International Prostate Symptom Score (IPSS) and variables of uroflowmetry. Secondary outcome measures included changes in prostate size, residual urinary volume after voiding, laboratory values and the reported adverse effects.

RESULTSG. lucidum was effective and significantly superior to placebo for improving total IPSS with 2.1 points decreasing at the end of treatment (mean difference, -1.18 points; 95% confidence interval, -1.74 to -0.62; P < 0.0001). No changes were observed with respect to quality of life scores, peak urinary flow, mean urinary flow, residual urine, prostate volume, serum prostate-specific antigen or testosterone levels. Overall treatment was well tolerated with no severe adverse effects.

CONCLUSIONThe extract of G. lucidum was well tolerated and improved IPSS scores. These results encouraged a further, large-scale evaluation of phytotherapy for a long duration using the extract of G. lucidum on men with LUTS.

Aged ; Drugs, Chinese Herbal ; administration & dosage ; adverse effects ; Ethanol ; Humans ; Male ; Middle Aged ; Phytotherapy ; Placebos ; Reishi ; Solvents ; Treatment Outcome ; Urination Disorders ; drug therapy ; Urodynamics ; drug effects

AIMTo conduct a double-blind, placebo-controlled randomized and dose-ranging study to evaluate the safety and efficacy of the extract of Ganoderma lucidum (G. lucidum) in men with lower urinary tract symptoms (LUTS).

METHODSWe enrolled male volunteers (> or = 50 years) with an International Prostate Symptom Score (IPSS; questions 1-7) > or = 5 and a prostate-specific antigen (PSA) value < 4 ng/mL. Volunteers were randomized into groups of placebo (n = 12), G. lucidum of 0.6 mg (n = 12), 6 mg (n = 12) or 60 mg (n = 14), administered once daily. Efficacy was measured as a change from baseline in IPSS and the peak urine flow rate (Q(max)). Prostate volume and residual urine were estimated by ultrasonography, and blood tests, including PSA levels, were measured at baseline and at the end of the treatment.

RESULTSThe overall administration was well tolerated, with no major adverse effects. Statistical significances in the magnitude of changes between the experimental groups were observed at weeks 4 and 8. No changes were observed with respect to Q(max), residual urine, prostate volume or PSA levels.

CONCLUSIONThe extract of G. lucidum was well tolerated and an improvement in IPSS was observed. The recommended dose of the extract of G. lucidum is 6 mg in men with LUTS.

Aged ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drugs, Chinese Herbal ; adverse effects ; therapeutic use ; Humans ; Male ; Middle Aged ; Phytotherapy ; methods ; Pilot Projects ; Prostate ; pathology ; Prostate-Specific Antigen ; blood ; Prostatic Hyperplasia ; drug therapy ; Reishi ; Treatment Outcome ; Urinary Bladder, Overactive ; drug therapy ; Urinary Incontinence ; drug therapy